PTCH2 and familial pancreatic carcinoma: Of particular interest, Smoothened-dependent GDC-0449 treatment of pancreatic CSCs markedly inhibited expressions of SHH receptors (Patched-1, Patched-2 and Smoothened) and effectors (Gli1 and Gli2), thereby showing potential for therapeutic application for treatment of pancreatic cancer.